特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病)(Idiopathic Thrombocytopenic Purpura)：治療薬開発パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Overview 8
Therapeutics Development 9
Pipeline Products for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Overview 9
Pipeline Products for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Comparative Analysis 10
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Therapeutics under Development by Companies 11
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Products under Development by Companies 15
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Companies Involved in Therapeutics Development 16
Anthera Pharmaceuticals‚ Inc. 16
Azano Pharmaceuticals Inc. 17
Boehringer Ingelheim GmbH 18
Bristol-Myers Squibb Company 19
Eisai Co., Ltd. 20
GlaxoSmithKline plc 21
HanAll Biopharma Co., Ltd. 22
Immunomedics, Inc. 23
Merck & Co., Inc. 24
Momenta Pharmaceuticals, Inc. 25
Pfizer Inc. 26
PhytoHealth Corporation 27
Rigel Pharmaceuticals, Inc. 28
SuppreMol GmbH 29
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Target 31
Assessment by Mechanism of Action 33
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
Antibody for Autoimmune Disorders and Inflammation – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
avatrombopag – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
AZ-175 – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
belimumab – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
BI-655064 – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
blisibimod – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
BMS-986004 – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
eltrombopag olamine – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
fostamatinib disodium – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
GL-2045 – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
GSK-2285921 – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
HL-161 – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
MK-8723 – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
PHN-013 – Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
SM-101 – Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
veltuzumab – Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Recent Pipeline Updates 67
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Dormant Projects 81
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Discontinued Products 82
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Product Development Milestones 83
Featured News & Press Releases 83
Feb 06, 2015: GSK announces EU regulatory submission seeking additional indication for eltrombopag (Revolade) 83
Dec 22, 2014: GSK announces US regulatory submission seeking additional indication for eltrombopag (Promacta) 83
Jul 16, 2014: Rigel Initiates Phase 3 Studies of Fostamatinib in ITP 83
Dec 09, 2013: Immunomedics Reports Promising Activity With Veltuzumab In Relapsed Immune Thrombocytopenia 84
Oct 24, 2013: Rigel Provides Update On Oral SYK Inhibitor Fostamatinib 85
Jul 24, 2013: NICE says yes to blood disorder treatment in final guidance 85
Jun 12, 2013: GSK’s Revolade Receives Positive Recommendation From NICE For Treatment Of Idiopathic Thrombocytopenic Purpura 86
Mar 20, 2013: GSK’s Eltrombopag Receives NICE Recommendation For Treatment Of Chronic Immune Thrombocytopenic Purpura 86
Dec 18, 2012: NICE Recommends GlaxoSmithKline’s Eltrombopag For Treatment Of Chronic Immune Thrombocytopenic Purpura 87
Dec 11, 2012: Immunomedics Provides Clinical Updates On Subcutaneous Injections Of Veltuzumab In Autoimmune Disease And Cancer 88
Appendix 90
Methodology 90
Coverage 90
Secondary Research 90
Primary Research 90
Expert Panel Validation 90
Contact Us 90
Disclaimer 91